Literature DB >> 22194019

Comparison of lipoprotein separation and lipid analysis methodologies for human and cynomolgus monkey plasma samples.

Seongah Han1, Amy M Flattery, David McLaren, Richard Raubertas, Sang Ho Lee, Vivienne Mendoza, Ray Rosa, Neil Geoghagen, Jose M Castro-Perez, Thomas P Roddy, Gail Forrest, Douglas Johns, Brian K Hubbard, Jing Li.   

Abstract

To assess cardiovascular risk in both clinical and basic research settings, it is imperative to be able to accurately measure plasma lipid levels. Here, methods commonly used to measure lipoproteins and lipids: ultracentrifugation (UC), fast protein liquid chromatography (FPLC), Roche auto-analyzer, and enzymatic assays were tested and compared. Plasma samples from 20 healthy humans and 22 cynomolgus monkeys were analyzed for their total cholesterol (TC), cholesterol in low density lipoproteins (LDL) and high density lipoproteins (HDL), and triglycerides (TG). Major lipid classes from UC and FPLC separated lipoprotein fractions from human plasma were further characterized by liquid chromatography-mass spectrometry analysis. All the tested methods showed acceptable performance with Roche analyzer among the best in approximate dilution linearity and recovery for most lipids as well as in repeatability between measurements of the same samples. TC, LDL, HDL, and TG values measured in human vs. monkey were-183.9 ± 35.5 (mean ± SD) vs. 105.6 ± 24.6 mg/dl, 106.0 ± 30.1 vs. 42.8 ± 13.0 mg/dl, 50.0 ± 11.4 vs. 53.4 ± 14.8 mg/dl, and 107.6 ± 50.7 vs. 58.0 ± 52.3 mg/dl. While no single method was uniformly the best, we recommend the Roche analyzer for routine measurements. UC or FPLC separation is needed for further functional characterization for specific lipid fraction. We have shown athero-protective profile in cynomolgus monkey compared with humans.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22194019     DOI: 10.1007/s12265-011-9340-9

Source DB:  PubMed          Journal:  J Cardiovasc Transl Res        ISSN: 1937-5387            Impact factor:   4.132


  28 in total

1.  Comparison of direct methods and HPLC for the measurement of HDL- and LDL-cholesterol with ultracentrifugation.

Authors:  A Yoshida; M Naito; M Kodama; H Nomura
Journal:  J Atheroscler Thromb       Date:  2001       Impact factor: 4.928

2.  High fat and high fructose diet induced intracranial atherosclerosis and enhanced vasoconstrictor responses in non-human primate.

Authors:  Masakazu Suzuki; Daisuke Yamamoto; Teruo Suzuki; Masanori Fujii; Nobuo Suzuki; Masato Fujishiro; Takanobu Sakurai; Kiyofumi Yamada
Journal:  Life Sci       Date:  2006-09-12       Impact factor: 5.037

3.  Comprehensive LC-MS E lipidomic analysis using a shotgun approach and its application to biomarker detection and identification in osteoarthritis patients.

Authors:  Jose M Castro-Perez; Jurre Kamphorst; Jeroen DeGroot; Floris Lafeber; Jeff Goshawk; Kate Yu; John P Shockcor; Rob J Vreeken; Thomas Hankemeier
Journal:  J Proteome Res       Date:  2010-05-07       Impact factor: 4.466

Review 4.  Declaring war on undertreatment: rationale for an aggressive approach to lowering cholesterol.

Authors:  Marjel van Dam; Sanne van Wissen; John J P Kastelein
Journal:  J Cardiovasc Risk       Date:  2002-04

5.  Evolution of methods for measurement of HDL-cholesterol: from ultracentrifugation to homogeneous assays.

Authors:  G R Warnick; M Nauck; N Rifai
Journal:  Clin Chem       Date:  2001-09       Impact factor: 8.327

6.  Genetic factors influence the atherogenic response of lipoproteins to dietary fat and cholesterol in nonhuman primates.

Authors:  L L Rudel
Journal:  J Am Coll Nutr       Date:  1997-08       Impact factor: 3.169

7.  A phenotype-sensitizing Apoe-deficient genetic background reveals novel atherosclerosis predisposition loci in the mouse.

Authors:  Hayes M Dansky; Pei Shu; M Donavan; Jill Montagno; Deborah L Nagle; John S Smutko; Natalie Roy; S Whiteing; Judith Barrios; T J McBride; Jonathan D Smith; Geoffrey Duyk; Jan L Breslow; Karen J Moore
Journal:  Genetics       Date:  2002-04       Impact factor: 4.562

8.  Plasma lipoprotein profile in the male cynomolgus monkey under normal, hypogonadal, and combined androgen blockade conditions.

Authors:  Mathias Leblanc; Marie-Claire Bélanger; Pierre Julien; André Tchernof; Claude Labrie; Alain Bélanger; Fernand Labrie
Journal:  J Clin Endocrinol Metab       Date:  2004-04       Impact factor: 5.958

9.  Low plasma HDL-c, a vascular risk factor in high risk patients independent of LDL-c.

Authors:  G R Hajer; Y van der Graaf; M L Bots; A Algra; F L J Visseren
Journal:  Eur J Clin Invest       Date:  2009-05-12       Impact factor: 4.686

10.  High ratio of triglycerides to HDL-cholesterol predicts extensive coronary disease.

Authors:  Protasio Lemos da Luz; Desiderio Favarato; Jose Rocha Faria-Neto; Pedro Lemos; Antonio Carlos Palandri Chagas
Journal:  Clinics (Sao Paulo)       Date:  2008-08       Impact factor: 2.365

View more
  8 in total

1.  Structural basis of the lipid transfer mechanism of phospholipid transfer protein (PLTP).

Authors:  Meng Zhang; Xiaobo Zhai; Jinping Li; John J Albers; Simona Vuletic; Gang Ren
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2018-06-05       Impact factor: 4.698

2.  Evaluation of CETP activity in vivo under non-steady-state conditions: influence of anacetrapib on HDL-TG flux.

Authors:  David G McLaren; Stephen F Previs; Robert D Phair; Steven J Stout; Dan Xie; Ying Chen; Gino M Salituro; Suoyu S Xu; Jose M Castro-Perez; Gregory J Opiteck; Karen O Akinsanya; Michele A Cleary; Hayes M Dansky; Douglas G Johns; Thomas P Roddy
Journal:  J Lipid Res       Date:  2015-12-09       Impact factor: 5.922

3.  ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys.

Authors:  Viktoria Gusarova; Corey A Alexa; Yan Wang; Ashique Rafique; Jee Hae Kim; David Buckler; Ivory J Mintah; Lisa M Shihanian; Jonathan C Cohen; Helen H Hobbs; Yurong Xin; David M Valenzuela; Andrew J Murphy; George D Yancopoulos; Jesper Gromada
Journal:  J Lipid Res       Date:  2015-05-11       Impact factor: 5.922

4.  Effects of small interfering RNA-mediated hepatic glucagon receptor inhibition on lipid metabolism in db/db mice.

Authors:  Seongah Han; Taro E Akiyama; Stephen F Previs; Kithsiri Herath; Thomas P Roddy; Kristian K Jensen; Hong-Ping Guan; Beth A Murphy; Lesley A McNamara; Xun Shen; Walter Strapps; Brian K Hubbard; Shirly Pinto; Cai Li; Jing Li
Journal:  J Lipid Res       Date:  2013-07-04       Impact factor: 5.922

5.  Aged Monkeys Fed a High-Fat/High-Sugar Diet Recapitulate Metabolic Disorders and Cardiac Contractile Dysfunction.

Authors:  Shuang Zheng; Weijiang Tan; Xiang Li; Binglin Li; Baoyong Gong; W Glen Pyle; Jian Wu; Lei Li; Ting Luo; Yunzeng Zou; Feng Hua Yang; Peter H Backx
Journal:  J Cardiovasc Transl Res       Date:  2021-02-16       Impact factor: 4.132

6.  HDL surface lipids mediate CETP binding as revealed by electron microscopy and molecular dynamics simulation.

Authors:  Meng Zhang; River Charles; Huimin Tong; Lei Zhang; Mili Patel; Francis Wang; Matthew J Rames; Amy Ren; Kerry-Anne Rye; Xiayang Qiu; Douglas G Johns; M Arthur Charles; Gang Ren
Journal:  Sci Rep       Date:  2015-03-04       Impact factor: 4.379

7.  Dose-dependent effects of siRNA-mediated inhibition of SCAP on PCSK9, LDLR, and plasma lipids in mouse and rhesus monkey.

Authors:  Kristian K Jensen; Marija Tadin-Strapps; Sheng-Ping Wang; James Hubert; Yanqing Kan; Yong Ma; David G McLaren; Stephen F Previs; Kithsiri B Herath; Ablatt Mahsut; Andy Liaw; Shubing Wang; Steven J Stout; CarolAnn Keohan; Gail Forrest; David Coelho; Satya Yendluri; Stephanie Williams; Martin Koser; Steven Bartz; Karen O Akinsanya; Shirly Pinto
Journal:  J Lipid Res       Date:  2016-10-05       Impact factor: 5.922

8.  Assessing the mechanisms of cholesteryl ester transfer protein inhibitors.

Authors:  Meng Zhang; Dongsheng Lei; Bo Peng; Mickey Yang; Lei Zhang; M Art Charles; Kerry-Anne Rye; Ronald M Krauss; Douglas G Johns; Gang Ren
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2017-09-12       Impact factor: 4.698

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.